New pharmacological agents under clinical investigation for treating disorders of lipoprotein regulation leading to atherosclerosis

Expert Opinion on Investigational Drugs

Volumn 10, Issue 3, 2001, Pages 561-567

  Gallup, E ^a   Dujovne, C ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

Anti atherosclerotics; Antilipidaemics; Dyslipidaemias; Hypolipidaemic drugs; Lipid acting drug; Lipoprotein regulator drugs; Lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SODIUM CHLORIDE; SODIUM ION; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROSIS; BILE ACID METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL RESEARCH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; HYPERCHOLESTEROLEMIA; INDUSTRIALIZATION; ISCHEMIC HEART DISEASE; LIVER; MORBIDITY; MORTALITY; REGULATORY MECHANISM; RISK ASSESSMENT;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS;

EID: 0035113858     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.3.561     Document Type: Article

References (29)

1. Screening asymptomatic adults for cardiac risk factors: The serum cholesterol
2. Summary of the second report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults
3. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
4. Bile acids regulate hepatic low-density lipoprotein receptor activity in the hamster by altering cholesterol flux across the liver
5. Mechanisms for the intestinal absorption of bile acids
6. New insights into bile acid transport
7. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter
8. Effective lipid modification by partial bypass reduced long-term coronary heart disease mortality and morbidity: Five-year post trial follow-up report from the POSCH
9. Well compensated primary bile acid malabsorption presenting as chronic nonspecific diarrhea
10. Fecal and biliary bile acid patterns in children with bile acid malabsorption
11. Hypercholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
12. Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in apo E knockout mice with and without LDL receptors
13. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: Results of a multicenter dose-ranging study
14. Severe atherosclerosis in transgenic mice expressing simian ester transfer protein
15. Increased high density lipoprotein caused by a common cholesteryl ester transfer protein gene mutation
16. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol ester transfer protein deficiency
17. Human plasma CETP deficiency: Identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America
18. Increased coronary heart disease in Japanese-American men with mutations in the CETP despite increased HDL levels
19. Effect of atorvastatin on hemorheologichemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
20. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
21. PPAR α and PPAR γ activators direct a distinct tissue-specific transcriptional response via PPRE in the lipoprotein lipase gene
22. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins and apolipoproteins, in patients with combined hyperlipidemia
23. The Acyl-CoA cholesterol acyltransferase (ACAT) inhibitor avasamibe reduces atherosclerosis independently of its lipid-lowering effect in apoE3-leiden mice
24. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs
25. ACAT inhibitor avasimibe lowers VLDL and TG in patients with hypertriglyceridemia
26. Serial evaluation of atherosclerosis with in vivo MRI: Study of atorvastatin and avasimibe in WHHL rabbits
27. Screening asymptotic adults for cardiac risk factors: The serum cholesterol level